| Bioactivity | SARS-CoV-2-IN-36 is a potent SARS-CoV-2 Mpro (SARS-CoV) inhibitor with an IC50 of 2.37 μM and a Kd of 1.19 μM in enzymatic assays. SARS-CoV-2-IN-36 shows antiviral activity against UC-1074, RG2674, and NVDBB-2220 SARS-CoV-2 variants in Vero cells[1]. |
| Invitro | SARS-CoV-2-IN-36 (compound 58) inhibit the replication of the Wuhan (UC-1074),South African (RG2674), and UK (NVDBB-2220) SARS-CoV-2 variants, with IC50 values of 5.0 μM, 39.9 μM, and 5.2 μM, respectively. SARS-CoV-2-IN-36 alters cell morphology only at concentrations above ≥100 μM and does not inhibit Vero cell growth up to a concentration >100 μM[1].SARS-CoV-2-IN-36 (compound 58) lacks antiviral activity against two herpesviruses (varicella-zoster virus and human cytomegalovirus) in human embryonic lung fibroblasts. SARS-CoV-2-IN-36 shows a very low cytotoxicity also against embryonic lung fibroblasts[1]. |
| In Vivo | PK analysis of plasma concentrations, with ± SD, after intranasal (IN) and oral (PO) administration in male C57BL6 mice[1]. Route |
| Name | SARS-CoV-2-IN-36 |
| Formula | C17H21N5O3 |
| Molar Mass | 343.38 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Simone Di Micco, et al. Rational design of the zonulin inhibitor AT1001 derivatives as potential anti SARS-CoV-2. Eur J Med Chem. 2022 Dec 15;244:114857. |